Adco-Alzam

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Adco-Alzam

Property Description
Active ingredient Alprazolam
Form Oral tablet (immediate-release)
Pharmacological class Benzodiazepine / Anxiolytic
Common use Relief of tension and anxiety
Origin Synthetic compound

What Type of Medicine is Adco-Alzam and What is its Composition?

Adco-Alzam is a pharmaceutical preparation that contains Alprazolam as its sole active ingredient, a chemically synthetic compound classified as a triazolo-benzodiazepine. This medication is typically manufactured and regulated for distribution in specific regions, such as South Africa, and is supplied as a single-ingredient product, primarily available in the form of an oral tablet intended for ingestion via the oral route of administration. The specific structure of Alprazolam places it within the broader benzodiazepine class of psychotropic agents. This formulation focuses on the rapid, measured delivery of the active substance, distinguishing it from extended-release versions and underscoring its intended use for acute symptom management.

General Purpose and Pharmacological Class of Alprazolam

The primary function of Alprazolam is defined by its designation as an anxiolytic, a specific type of medicine clinically recognized and used to rapidly relieve anxiety and its associated somatic symptoms. It achieves this by functioning as a central nervous system (CNS) depressant. A comprehensive review on the substance confirmed its efficacy and established its high-level classification among fast-acting anti-anxiety treatments. The core mechanism involves selectively enhancing the effects of Gamma-aminobutyric acid (GABA), the brain's major inhibitory neurotransmitter, thereby promoting a state of natural calm. Consequently, the general therapeutic purpose of this sedative-hypnotic agent is to provide rapid relief from the excessive tension, agitation, and physiological distress associated with high anxiety.

Regulatory References

  1. MedlinePlus Drug Information on Alprazolam
  2. FDA label for Alprazolam
Advertisements

What side effects are possible with Adco-Alzam?

Possible side effects and safety information

The safety profile of Adco-Alzam, which contains Alprazolam, is primarily characterized by effects related to its action as a Central Nervous System (CNS) depressant, according to regulatory documentation. The most frequently reported adverse reactions are classified by frequency and grouped by System-Organ Class (SOC) categories, such as Nervous System Disorders and Psychiatric Disorders.

Officially Documented Adverse Reactions

Classification Common Examples
Very Common (≥ 1/10) Sedation, Somnolence, Fatigue, Depression
Common (≥ 1/100 to < 1/10) Ataxia (impaired coordination), Dizziness, Memory impairment, Constipation, Dry mouth

Serious Safety Considerations

The most significant safety constraint is the potential for developing physical and psychological dependence. Regulatory labels emphasize the risk of a severe withdrawal syndrome following abrupt or rapid cessation. Other serious reactions documented include rare Paradoxical Reactions (such as agitation or hostility) and the risk of profound sedation and respiratory depression, especially when used concurrently with opioids, a risk noted by a Boxed Warning in the U.S. regulatory information.

Population and Exposure Constraints

Specific safety considerations are noted for certain groups. Older adults may have increased sensitivity to the CNS depressant effects, which increases the risk of falls. The medicine is generally contraindicated in individuals with severe hepatic insufficiency and in patients with acute narrow-angle glaucoma. Furthermore, effects like Sedation are more likely to occur at the initiation of treatment, while tolerance and dependence are primarily associated with long-term use.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose manifestations described in regulatory documents primarily involve progressive Central Nervous System (CNS) depression. These presentations range from mild signs, such as excessive drowsiness (somnolence), confusion, impaired coordination (ataxia), and slurred speech, to more severe and potentially life-threatening outcomes.

Severe overdose outcomes documented in official labeling include coma, profound respiratory depression, and, ultimately, death. Regulatory information emphasizes that the risk of these life-threatening effects is significantly increased when Adco-Alzam is combined with other CNS depressants, notably alcohol and opioid medicines.

Authorities mandate that immediate medical attention or emergency medical care must be sought for any suspected overdose or the appearance of severe symptoms. This action is critical for signs such as extreme sleepiness, breathing difficulties, or loss of consciousness.

Management is defined as primarily symptomatic and supportive treatment, with continuous observation necessary for the monitoring of vital signs and respiratory status. The agent Flumazenil may be considered by medical professionals to reverse benzodiazepine-induced CNS depression, but its use is carefully constrained due to the official documentation of potential risks, such as precipitating seizures. Elderly patients and individuals with hepatic or renal impairment are noted in regulatory information to be more susceptible to the severity and duration of overdose effects.

Advertisements

Therapeutic Uses of Adco-Alzam

What Adco-Alzam Treats: Main Uses and Benefits

The primary role of Adco-Alzam (Alprazolam) is to provide supportive symptomatic relief in therapeutic areas characterized by increased emotional distress and physical tension. It is commonly used in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is appropriate for temporary stabilization. It is indicated for the management of specific anxiety and panic disorders.

This medication is generally applied in conditions such as Generalized Anxiety Disorder (GAD) and Panic Disorder, addressing symptoms that may appear alongside depression. It helps address symptom clusters that include apprehension, mental tension, and chronic worry that leads to noticeable functional strain. The key benefit supports patients by easing distress during difficult periods, which assists with maintaining functional stability.

Quick Fact: Support for Acute Episodes

Adco-Alzam assists with easing the overall burden of panic and the distressing physical symptoms that accompany it, such as trembling or symptoms related to heightened physiological activity. It is used in settings where short-term symptom stabilization is important.

Advertisements

Eligibility and Restrictions for Use

Official Population Eligibility for Adco-Alzam (Alprazolam)

Adco-Alzam (Alprazolam) is typically authorized for use in adult patients (18 years and older). Regulatory documents impose specific, strict eligibility constraints based on a patient’s medical status, age, and concurrent treatments.

Populations for Whom Use is Contraindicated

Official labeling strictly prohibits the use of this medicine in the following populations and conditions:

  • Patients with known hypersensitivity (allergy) to alprazolam or other benzodiazepine medicines.
  • Patients with acute narrow-angle glaucoma.
  • Patients with Myasthenia gravis, severe respiratory insufficiency, or sleep apnoea syndrome (as per European-based prescribing information).
  • Patients with severe hepatic insufficiency.
  • Patients receiving certain strong CYP3A enzyme inhibitors (e.g., ketoconazole, itraconazole).

Age-Related and Conditional Use Restrictions

Population Group Official Regulatory Status
Children and Adolescents (Under 18) Not recommended; safety and efficacy have not been established in this age group.
Older Adults (Geriatric) Eligible, but use requires caution and starting with a lower initial dose to reduce the risk of over-sedation.
Pregnancy Caution required; use in later pregnancy may cause neonatal sedation or neonatal withdrawal syndrome.
Lactation Breastfeeding is not recommended as the substance is known to be excreted into human milk.
Impaired Organ Function Patients with impaired renal function or mild to moderate hepatic insufficiency must use the medicine with caution and may require dose reduction.

These eligibility rules define the required population constraints, and use is exclusively limited to adults under the specified conditions.

Advertisements

What should I know about interactions with other medicines?

Adco-Alzam (which contains alprazolam) can interact with a wide range of other medicines and products, potentially changing how it works or increasing the risk of serious side effects, such as slowed or stopped breathing and excessive sedation.

Combinations to Avoid

Co-administration with ketoconazole or itraconazole is contraindicated, as these strong CYP3A4 inhibitors can significantly increase the level of alprazolam in the body. Concomitant use with opioid medicines (such as codeine, oxycodone, or fentanyl) and alcohol is strongly discouraged due to the major risk of extreme drowsiness, respiratory depression, coma, and death. Patients should also avoid consuming grapefruit or grapefruit juice.


️ Caution and Dosage Adjustment Required

Tell your healthcare provider if you are taking any of the following, as dosage adjustments or close monitoring may be necessary:

Drug Class / Examples Effect of Interaction
Other CNS Depressants: sleep aids (e.g., zolpidem), muscle relaxants (e.g., cyclobenzaprine) Increased risk of drowsiness, sedation, and breathing problems.
Certain Antidepressants: fluvoxamine, nefazodone, fluoxetine May increase Adco-Alzam levels, leading to increased effects.
Other CYP3A4 Inhibitors: certain antibiotics (e.g., clarithromycin), cimetidine Can increase Adco-Alzam plasma concentrations.
CYP3A4 Inducers: carbamazepine, phenytoin, St. John's wort May decrease the effectiveness of Adco-Alzam.
Digoxin May increase the risk of digoxin-related toxicity.

Always disclose all prescription, over-the-counter, and herbal products, as well as vitamins and supplements, to your doctor or pharmacist to safely manage potential interactions.

Advertisements

Mechanism of Action

Adco-Alzam, which contains the active compound alprazolam, acts within the central nervous system (CNS). Its primary molecular target is the GABA-A receptor complex, a ligand-gated chloride ion channel. The drug functions as a positive allosteric modulator of this receptor.

Alprazolam binds specifically to the benzodiazepine binding site, which is located at the interface of the alpha and gamma subunits of the GABA-A receptor. This interaction does not directly activate the ion channel but facilitates a conformational change that increases the affinity of the receptor for its endogenous agonist, gamma-aminobutyric acid (GABA).

The downstream cascade involves an increased frequency of chloride ion channel opening in response to GABA binding. This results in an increased influx of negatively charged chloride ions into the postsynaptic neuron. The augmented chloride conductance leads to neuronal hyperpolarization, which consequently stabilizes the resting membrane potential and makes the neuron less excitable.

The system-level physiological consequence is a widespread depression of synaptic transmission in the CNS, leading to a modulation of neuronal activity in brain regions associated with wakefulness and emotional processing.

Advertisements

Dosage and Administration Information

Adco-Alzam (Alprazolam Immediate-Release) is administered via the oral route and is available in tablet strengths ranging from 0.25 mg to 2 mg. The standard protocol specifies that the medicine is taken in divided doses, typically three times daily, and may be ingested without regard to food.

Dosing is defined by the condition being managed. For Generalized Anxiety Disorder (GAD), the typical starting dosage is between 0.25 mg and 0.5 mg three times daily, with the maximum recommended daily dose generally not exceeding 4 mg. For Panic Disorder, the initial dose is 0.5 mg three times daily. Any dosage adjustment must be done gradually, at intervals of every 3 to 4 days.

Specific populations are designated a lower initial dose. For both older adults and patients with severe hepatic impairment, a starting dose of 0.25 mg administered two or three times daily is specified, a procedural modification to account for altered physiological processing.

The usage pattern requires that the necessity of continued treatment be frequently reassessed. When discontinuing the medication, the dose must be reduced gradually, a process known as tapering. Guidelines state the dose should be decreased by no more than 0.5 mg every 3 days. Clinical studies supporting efficacy for GAD were limited to four months, emphasizing the requirement for periodic re-evaluation.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

Phase 3 Clinical Trials

Research has evaluated whether the drug is associated with a reduction in symptoms for patients with severe, chronic condition X. These trials focused on adults diagnosed with the condition for at least five years.

  • Primary Outcome: The main measure explored was the change in a standardized symptom scale score after 12 weeks of treatment.
  • Study Population: The two pivotal trials involved a total of 1,250 participants across 10 countries.

Early phase trials reported findings that examined potential outcomes, including comparisons to other treatments. Specifically, studies explored whether the drug was associated with changes in pain and mobility. One study explored the time to observation of changes in symptoms.

Secondary Findings and Combination Therapy

Additional research evaluated outcomes for specific subgroups and explored combination approaches.

  • Subgroup Analysis: Studies examined patients with co-morbidities B and C. Specific study results varied in these groups compared to the overall study population.
  • Combination Treatment: Studies evaluated outcomes when combining therapies compared to using monotherapy for this patient group. This research focused on the overall safety profile and whether the combination was associated with fewer adverse events.

Safety and Tolerability

The safety profile was assessed across all phases of the research, with studies focusing on the incidence of common adverse events and participant discontinuation rates related to adverse events.

  • Specific Patient Groups: Research has examined the outcomes for patients with liver condition A who were administered the drug. Further research is ongoing to examine the outcomes in patients with pre-existing conditions.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Adco-Alzam (FAQ)

Q: How quickly does Adco-Alzam typically start to show its intended effects?

Adco-Alzam is absorbed quickly after it is taken. According to official prescribing information, the concentration of the active drug in the blood typically reaches its peak within 1 to 2 hours.


Q: How long does one dose of Adco-Alzam usually last in the body?

The drug’s elimination half-life, which is the time it takes for half of the dose to be removed from the body, averages about 11 hours in healthy adults. This duration may be longer for certain individuals, such as older adults or people with specific liver conditions.


Q: What happens if I accidentally miss a dose of Adco-Alzam?

General medical guidance states that if a missed dose is remembered, it is typically advised to be taken promptly. However, if it is already close to the time for the next scheduled dose, it may be necessary to skip the missed dose and follow the regular schedule. This is to avoid taking too much medicine at once.


Q: Are there any common foods or drinks that I should avoid while on Adco-Alzam?

Regulatory documents include a warning about consuming grapefruit or grapefruit juice while using Adco-Alzam. These products can interfere with the way the body breaks down the medicine, potentially leading to increased levels of the drug in the blood and a higher risk of side effects.


Q: Can older adults use Adco-Alzam, and is the experience different for them?

Yes, older adults are generally eligible to use Adco-Alzam, but regulatory information indicates they may be more sensitive to its effects. This increased sensitivity can lead to a higher risk of side effects like excessive sedation or falls. Official prescribing information specifies that a lower starting dose is usually specified for older adults.


Q: What is the risk of having a serious allergic reaction to Adco-Alzam?

A known allergy or hypersensitivity to Adco-Alzam or other medicines in its class is a condition that officially prohibits its use. If signs of a severe allergic reaction, such as swelling or rapid heartbeat, are observed, it is important to contact a healthcare professional.


Q: What official research evidence is available regarding the long-term use of Adco-Alzam?

The primary systematic clinical studies supporting the effectiveness of Adco-Alzam for anxiety disorder were generally limited to a duration of four months. Due to this, official prescribing information emphasizes the requirement for frequent re-evaluation by a healthcare professional.


Q: Can people who are lactose intolerant safely take Adco-Alzam tablets?

The official description of Adco-Alzam tablets lists lactose as one of the inactive ingredients used in the product. Patients with known lactose intolerance are advised to review this ingredient with their healthcare provider.


Q: Is Adco-Alzam linked to any memory problems?

Yes, official adverse event listings indicate that memory impairment is a common side effect reported by patients using Adco-Alzam (alprazolam) in clinical studies.


Q: Is Adco-Alzam linked to any long-term gastrointestinal problems?

Common gastrointestinal side effects noted in official regulatory documents include constipation and dry mouth. Other changes, such as in appetite or weight, are also noted as less common possible effects.


Q: What is the typical duration of treatment with Adco-Alzam as described by regulators?

Because the systematic clinical trials supporting its use were typically limited to four months, regulatory documents require that the necessity of treatment be re-evaluated frequently. The duration of use should be limited to the minimum time judged necessary.


Q: Is Adco-Alzam a type of sleeping pill or something different?

Adco-Alzam is classified as a central nervous system (CNS) depressant. While it does have sedative properties that may help people relax, its primary purpose is officially defined as relieving tension and anxiety. It is not classified as a dedicated sleep medicine.


Q: Do I need to be worried about dependence if I take Adco-Alzam as prescribed?

Official regulatory warnings note that the drug has a potential to cause physical and psychological dependence. The risk is known to increase with longer periods of use and higher doses. For this reason, the use of this medication requires close medical supervision and monitoring.


Q: Is it true that Adco-Alzam might cause strange dreams or nightmares?

Yes, regulatory documents list dream abnormalities as a less common adverse event reported during clinical studies of the active ingredient, alprazolam.


Q: Is Adco-Alzam safe to use if I have existing kidney problems?

Patients with impaired kidney function must use Adco-Alzam with caution. Official guidance states that usual precautions, such as dose adjustment, should be observed to account for the body’s altered ability to process the medicine.


Q: Is there a known 'rebound' effect when people stop taking Adco-Alzam?

When the medication is stopped quickly or suddenly, official documents describe the risk of a severe withdrawal syndrome. This process can include a temporary worsening of the original symptoms and is the reason a gradual dose reduction, or tapering, is required.


Q: Is Adco-Alzam known to cause changes in appetite or weight?

Official reports on adverse events include both increased and decreased appetite, as well as both weight gain and weight loss, as less common effects that were reported during clinical studies.


Q: What makes Adco-Alzam different from a benzodiazepine?

Adco-Alzam is a brand name for the active ingredient alprazolam, which is classified as a triazolo-benzodiazepine. Therefore, it is officially a member of the benzodiazepine class of medicines.


Q: Are there any mental health conditions that would prevent someone from using Adco-Alzam?

In certain regions, official information may caution against or prohibit the use of the medicine in patients with severe depression or psychotic illnesses. Regulatory warnings also note that existing depression and suicidal ideation must be monitored closely.


Q: How does Adco-Alzam relate to sleep quality beyond just falling asleep?

As a central nervous system depressant, the medicine affects overall brain activity. Regulatory information notes that long-term use of this class of drugs may be associated with changes in the normal architecture of the sleep cycle, which is why periodic re-evaluation is necessary.


Q: Can Adco-Alzam make existing mood disorders feel worse?

Yes, official warnings and precautions state that Adco-Alzam can be associated with worsening or unmasking existing depression. The risk of suicidal ideation is also a specific concern noted in the warnings section.


Q: Are there any known ethnic or racial differences in how Adco-Alzam affects people?

Official regulatory pharmacokinetics data indicates that the highest concentration of the drug in the blood and its elimination time are observed to be higher in patients of Asian descent compared to Caucasian patients.


Q: What is considered an overdose of Adco-Alzam?

Taking too much Adco-Alzam (alprazolam) alone typically results in symptoms like severe drowsiness, confusion, and poor coordination. Regulatory documents emphasize that the most dangerous outcomes, such as coma and severe breathing problems, occur when it is taken with other CNS depressants.


Q: Is Adco-Alzam a new drug, or has it been used for many years?

The active ingredient in Adco-Alzam, alprazolam, was first approved and introduced for therapeutic use by regulatory authorities in the early 1980s. This means the medicine has been in clinical use for several decades.


Q: Does Adco-Alzam carry a risk for cardiac or heart issues?

While it is not a primary concern, regulatory documents note that severe reactions, particularly in cases of overdose, can be associated with changes such as a decrease in heart rate and blood pressure. Patients should report any experience of a rapid heartbeat.


Q: Are there different versions or formulations of Adco-Alzam available?

The active ingredient alprazolam is available in several different forms, including immediate-release oral tablets (like Adco-Alzam), extended-release tablets, and orally disintegrating tablets, depending on the manufacturer and region.


Q: Can Adco-Alzam be crushed or chewed, or must it be swallowed whole?

The immediate-release tablets are intended to be swallowed whole. Specific instructions for the different formulations (such as extended-release or sublingual types) strictly state that they must not be crushed or chewed.


Q: What does the research say about Adco-Alzam's effect on children and adolescents?

Regulatory information explicitly states that the safety and effectiveness of Adco-Alzam (alprazolam) have not been established in pediatric patients under 18 years of age. This lack of evidence is the basis for the recommendation against its use in this population.


Q: Why is it important to tell the doctor about all other medicines I take before starting Adco-Alzam?

It is important because many medicines, including certain antifungals and antidepressants, can block the key liver enzyme (CYP3A4) responsible for breaking down Adco-Alzam. This interference can cause the drug level in the body to rise to dangerous levels, increasing the risk of serious side effects like excessive sedation.


Q: Is the time of day when Adco-Alzam is taken important?

Yes, the medication is typically prescribed to be taken in divided doses, often throughout the day, in order to maintain a consistent amount of the drug in the bloodstream. Regular and scheduled dosing is therefore important for the intended effects.


Q: How does Adco-Alzam affect the body's natural sleep cycle?

As a central nervous system depressant, the medicine works by modulating brain activity. Regulatory information notes that long-term use of this class of medicines may be associated with changes in the normal architecture of the sleep cycle, which is why periodic re-evaluation is necessary.


Q: Does the gender of a person change how Adco-Alzam works?

Official regulatory pharmacokinetics studies found that a person's gender has no significant effect on how the body processes the active ingredient in Adco-Alzam (alprazolam).


Q: If I have a history of substance abuse, is Adco-Alzam appropriate for me?

Patients with a history of drug or alcohol abuse require close observation and monitoring. This is due to the potential for misuse, dependence, and addiction, which are risks noted in the official regulatory documents for this medication.

Advertisements

How should Adco-Alzam be stored and disposed of?

How to Store and Dispose of Adco-Alzam (Alprazolam)

Adco-Alzam tablets must be stored according to official regulatory requirements to ensure stability and safety, particularly due to its classification as a controlled substance.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing, and protect from moisture and light.
Container/Safety Must be kept in the original, tightly closed container and stored in a secure place.

The medication must be stored out of the reach of children.

Disposal Protocol

Unused or expired Adco-Alzam must be disposed of according to applicable local and national regulations. The official protocol prioritizes utilizing authorized drug take-back programs or DEA-registered collectors. If these are unavailable, federal guidelines permit household disposal by mixing the medicine with an unappealing substance, such as cat litter, sealing it in a bag, and discarding it in the trash. The medicine must not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adco-Alzam found in:

A-Z Index: